ERBB2 and breast carcinoma: A pooled analysis of the DEBBRAH, TUXEDO-1, and DFCI/Duke/MDACC studies confirmed the significant intracranial efficacy of T-DXd in HER2-positive breast cancer with active brain metastases, achieving an ORR-IC of 64.9% and a clinical benefit rate of 81.1%.